Maxcyte (DI) (MXCT)

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

161.00p
   
  • Change Today:
    -5.50p
  • 52 Week High: 253.00
  • 52 Week Low: 157.00
  • Currency: UK Pounds
  • Shares Issued: 51.36m
  • Volume: 11,351
  • Market Cap: £82.69m

Deal with Barclays    Trade now with Barclays Stockbrokers

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

By Josh White

Date: Wednesday 08 May 2019

LONDON (ShareCast) - (Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.
The AIM-traded firm described MCY-M11 as a mesothelin-targeting chimeric antigen receptor (CAR) therapy being tested in individuals with relapsed or refractory ovarian cancer and peritoneal mesothelioma.

It said the dose escalation trial was evaluating the safety and tolerability of MCY-M11 in approximately 15 patients across a series of cohorts.

"Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform," said chief medical officer Claudio Dansky Ullmann.

"We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options."

The manufacturing process for MCY-M11 utilised MaxCyte's proprietary 'Flow Electroporation' technology to transfect mRNA into fresh peripheral blood mononuclear cells (PBMCs), the company explained.

It said that streamlined, faster manufacturing process for an autologous cell therapy was an important differentiator from other CAR technologies.

In addition, the CARMA platform's utilisation of Flow Electroporation, rather than viral vectors, enabled repeat dosing of patients - a feature that it said could be key for the successful treatment of solid tumours with a cell therapy.

Another distinguishing feature of MaxCyte's CARMA platform was the insertion of the CAR as mRNA into cells, rather than as DNA.

The transient nature of mRNA could help alleviate some of the safety limitations of other CAR treatment approaches.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Maxcyte (DI) Market Data

Currency UK Pounds
Share Price 161.00p
Change Today -5.50p
% Change -3.30 %
52 Week High 253.00
52 Week Low 157.00
Volume 11,351
Shares Issued 51.36m
Market Cap £82.69m

Maxcyte (DI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Maxcyte (DI) Dividends

No dividends found

Trades for 14-Jun-2019

Time Volume / Share Price
15:55 300 @ 161.49p
13:10 117 @ 161.49p
13:08 2,000 @ 162.50p
12:15 3,113 @ 157.00p
12:07 1,000 @ 163.85p

Maxcyte (DI) Key Personnel

CEO Doug Doerfler
CFO Ron Holtz

Top of Page